Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01312272 · ClinicalTrials.gov registry record · NA
Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?
A NA study, sponsored by VA Greater Los Angeles Healthcare System.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT01312272 is a NA study that has completed, run by VA Greater Los Angeles Healthcare System. The registered enrollment target is 24 participants.
The verdict
NCT01312272, a NA study, has completed, sponsored by VA Greater Los Angeles Healthcare System.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
Individuals with schizophrenia have been found to have deficits in social cognition, which is defined as the functions that are engaged during social interactions. Social cognition has been found to be critical in predicting multiple aspects of community functioning. There are no currently available medications that have been consistently found to improve social cognition in individuals with schizophrenia. Oxytocin functions as a neurotransmitter that is thought to be involved in multiple aspects of social behavior and related emotions. In this study, we test the hypothesis that acute administration of intranasal oxytocin will improve social cognition in individuals with schizophrenia.
Interventions
- DRUG Oxytocin
- DRUG Inactive placebo nasal spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01312272
The ClinicalTrials.gov registry entry for NCT01312272 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Greater Los Angeles Healthcare System, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oxytocin is the first listed.
NCT01312272 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01312272 about?
NCT01312272 is a clinical study titled "Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?". Individuals with schizophrenia have been found to have deficits in social cognition, which is defined as the functions that are engaged during social interactions. Social cognition has been found to be critical in predicting multiple aspects of community functioning. There are no currently available...
What is the current status of trial NCT01312272?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2011-04. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01312272?
The interventions under investigation include: Oxytocin (DRUG), Inactive placebo nasal spray (DRUG).
Who is sponsoring clinical trial NCT01312272?
This trial is sponsored by VA Greater Los Angeles Healthcare System, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.